国产精品99一区二区三_免费中文日韩_国产在线精品一区二区_日本成人手机在线

Adjusting therapeutic steps a promising strategy for treating lung cancer: study

Source: Xinhua| 2018-04-16 23:39:15|Editor: Mu Xuequan
Video PlayerClose

WASHINGTON, April 16 (Xinhua) -- A study has shown that a new, innovative approach to lung cancer treatment in which immunotherapy is administered prior to surgery is yielding encouraging outcomes in 45 percent of non-small cell lung cancer patients treated.

In a study published on Monday in the New England Journal of Medicine, Scientists at Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy and Memorial Sloan Kettering Cancer Center administered two doses of the anti-PD1 immunotherapy nivolumab for several weeks prior to surgery.

The therapy turned out to be not only safe but 45 percent of the patients in the initial trial responded so well that there was little evidence of the cancer remaining upon follow-up.

According to the researchers, the patients' immune systems also likely destroyed straggler tumor cells still circulating in the blood system, which can later take hold and lead to recurrence and metastasis.

"The team is using T cells, activated by immunotherapy prior to surgery, to continue to circulate through the patient's body, after surgery. These T cells can intervene, stopping errant tumor cells from forming new metastases, preventing recurrence," said Sung Poblete, CEO of Stand Up To Cancer, a foundation that funded the research.

Previously, chemotherapy or chemoradiotherapy is given to lung cancer patients to shrink a large, non-metastasized tumor while immunotherapeutic agents have been administered after surgery with limited results.

However, the researchers hypothesized that leaving the tumor in place during initial treatment with immunotherapy would turn it into an "auto-vaccine."

The "auto-vaccine" might result in the activation of tumor-specific T cells that would then circulate through the body and find distant sites of micrometastases, thereby preventing relapse post-surgery which can happen to at least one-half of lung cancer patients who undergo surgery.

After a median follow-up of 12 months, three-quarters of the patients who underwent surgical resection were alive and recurrence-free. Recurrence-free survival at 18 months was 73 percent.

TOP STORIES
EDITOR’S CHOICE
MOST VIEWED
EXPLORE XINHUANET
010020070750000000000000011105091371156371
主站蜘蛛池模板: 延寿县| 宁德市| 博兴县| 孝感市| 盐边县| 晋江市| 文山县| 奉化市| 辽阳县| 大渡口区| 嘉善县| 资源县| 枣阳市| 阿合奇县| 东光县| 盖州市| 阿拉善左旗| 平泉县| 霍林郭勒市| 大足县| 治县。| 新沂市| 武宣县| 阳东县| 临桂县| 许昌市| 淮安市| 西宁市| 防城港市| 内丘县| 余庆县| 东乌珠穆沁旗| 阿城市| 营山县| 垣曲县| 中山市| 潼南县| 平舆县| 通渭县| 罗城| 江都市|